Literature DB >> 12972507

Selective inactivation of CCR5 and decreased infectivity of R5 HIV-1 strains mediated by opioid-induced heterologous desensitization.

Imre Szabo1, Michele A Wetzel, Ning Zhang, Amber D Steele, David E Kaminsky, Chongguang Chen, Lee-Yuan Liu-Chen, Filip Bednar, Earl E Henderson, O M Zack Howard, Joost J Oppenheim, Thomas J Rogers.   

Abstract

The opiates are well-established immunomodulatory factors, and recent evidence suggests that mu- and delta-opioid receptor ligands alter chemokine-driven chemotactic responses through the process of heterologous desensitization. In the present report, we sought to examine the capacity of mu- and delta-opioids to modulate the function of chemokine receptors CCR5 and CXCR4, the two major human immunodeficiency virus (HIV) coreceptors. We found that the chemotactic responses to the CCR1/5 ligand CCL5/regulated on activation, normal T expressed and secreted, but not the CXCR4 ligand stromal cell-derived factor-1alpha/CXCL12 were inhibited following opioid pretreatment. Studies were performed with primary monocytes and Chinese hamster ovary cells transfected with CCR5 and the micro-opioid receptor to determine whether cross-desensitization of CCR5 was a result of receptor internalization. Using radiolabeled-binding analysis, flow cytometry, and confocal microscopy, we found that the heterologous desensitization of CCR5 was not associated with a significant degree of receptor internalization. Despite this, we found that the cross-desensitization of CCR5 by opioids was associated with a decrease in susceptibility to R5 but not X4 strains of HIV-1. Our findings are consistent with the notion that impairment of the normal signaling activity of CCR5 inhibits HIV-1 coreceptor function. These results have significant implications for our understanding of the effect of opioids on the regulation of leukocyte trafficking in inflammatory disease states and the process of coreceptor-dependent HIV-1 infection. The interference with HIV-1 uptake by heterologous desensitization of CCR5 suggests that HIV-1 interaction with this receptor is not passive but involves a signal transduction process.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12972507     DOI: 10.1189/jlb.0203067

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  49 in total

Review 1.  Mechanisms regulating chemokine receptor activity.

Authors:  Laura D Bennett; James M Fox; Nathalie Signoret
Journal:  Immunology       Date:  2011-11       Impact factor: 7.397

2.  Far from the heart: Receptor cross-talk in remote conditioning.

Authors:  Christian Weber
Journal:  Nat Med       Date:  2010-07       Impact factor: 53.440

Review 3.  Chemokines: integrators of pain and inflammation.

Authors:  Fletcher A White; Sonia K Bhangoo; Richard J Miller
Journal:  Nat Rev Drug Discov       Date:  2005-10       Impact factor: 84.694

4.  CCR2 mediates increases in glial activation caused by exposure to HIV-1 Tat and opiates.

Authors:  Nazira El-Hage; Guanghan Wu; Jayakrishna Ambati; Annadora J Bruce-Keller; Pamela E Knapp; Kurt F Hauser
Journal:  J Neuroimmunol       Date:  2006-07-10       Impact factor: 3.478

Review 5.  Opioids and HIV/HCV infection.

Authors:  Xu Wang; Ting Zhang; Wen-Zhe Ho
Journal:  J Neuroimmune Pharmacol       Date:  2011-07-14       Impact factor: 4.147

6.  Interactions between chemokine and mu-opioid receptors: anatomical findings and electrophysiological studies in the rat periaqueductal grey.

Authors:  Silke Heinisch; Jonathan Palma; Lynn G Kirby
Journal:  Brain Behav Immun       Date:  2010-10-23       Impact factor: 7.217

Review 7.  Modulation of chemokine receptor activity through dimerization and crosstalk.

Authors:  C L Salanga; M O'Hayre; T Handel
Journal:  Cell Mol Life Sci       Date:  2009-04       Impact factor: 9.261

8.  Cross-desensitization of CCR1, but not CCR2, following activation of the formyl peptide receptor FPR1.

Authors:  Filip Bednar; Changcheng Song; Giuseppe Bardi; William Cornwell; Thomas J Rogers
Journal:  J Immunol       Date:  2014-04-28       Impact factor: 5.422

9.  An in vitro model of morphine withdrawal manifests the enhancing effect on human immunodeficiency virus infection of human T lymphocytes through the induction of substance P.

Authors:  Xu Wang; Steven D Douglas; Jin-Song Peng; Dun-Jin Zhou; Qi Wan; Wen-Zhe Ho
Journal:  Am J Pathol       Date:  2006-11       Impact factor: 4.307

10.  CCL5/RANTES gene deletion attenuates opioid-induced increases in glial CCL2/MCP-1 immunoreactivity and activation in HIV-1 Tat-exposed mice.

Authors:  Nazira El-Hage; Annadora J Bruce-Keller; Pamela E Knapp; Kurt F Hauser
Journal:  J Neuroimmune Pharmacol       Date:  2008-09-25       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.